歌礼制药：因化合物分子结构一致，石药集团附属公司对一项已获授权专利提出质疑

财经网2025-07-01

近日，歌礼制药发布自愿性公告。披露公司近日获悉由石药集团有限公司附属公司康久普乐生物医疗有限公司向美国专利商标局（“USPTO”）提交的一项复审。该复审质疑本公司附属公司歌礼制药（中国）有限公司一项已获授权的美国专利的有效性。截至本公告日期，该复审仍在USPTO审查中。石药尚在专利申请中的化合物10（Compound 10，申请号：PCT/CN2024/140920；申请人：石药集团百克（山东）...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2548026544?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-01 11:36","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2548026544","market":"hk","top_or_hot":-1,"title":"歌礼制药：因化合物分子结构一致，石药集团附属公司对一项已获授权专利提出质疑","media":"财经网","content":"<div>\n<p>近日，歌礼制药发布自愿性公告。披露公司近日获悉由石药集团有限公司附属公司康久普乐生物医疗有限公司向美国专利商标局（“USPTO”）提交的一项复审。该复审质疑本公司附属公司歌礼制药（中国）有限公司一项已获授权的美国专利的有效性。截至本公告日期，该复审仍在USPTO审查中。石药尚在专利申请中的化合物10（Compound 10，申请号：PCT/CN2024/140920；申请人：石药集团百克（山东）...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701114134a4c7fd2a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>歌礼制药：因化合物分子结构一致，石药集团附属公司对一项已获授权专利提出质疑</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n歌礼制药：因化合物分子结构一致，石药集团附属公司对一项已获授权专利提出质疑\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-01 11:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701114134a4c7fd2a&s=b><strong>财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，歌礼制药发布自愿性公告。披露公司近日获悉由石药集团有限公司附属公司康久普乐生物医疗有限公司向美国专利商标局（“USPTO”）提交的一项复审。该复审质疑本公司附属公司歌礼制药（中国）有限公司一项已获授权的美国专利的有效性。截至本公告日期，该复审仍在USPTO审查中。石药尚在专利申请中的化合物10（Compound 10，申请号：PCT/CN2024/140920；申请人：石药集团百克（山东）...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701114134a4c7fd2a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"欧康维视生物-B","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701114134a4c7fd2a&s=b","article_id":"2548026544","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701114134a4c7fd2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2548026544","pubTimestamp":1751340976,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"披露公司近日获悉由石药集团有限公司附属公司康久普乐生物医疗有限公司向美国专利商标局提交的一项复审。该复审质疑本公司附属公司歌礼制药（中国）有限公司一项已获授权的美国专利的有效性。基于其与现有技术相比具有新颖性和非显而易见性，USPTO已于2025年2月25日将该专利权授予本公司附属公司歌礼制药（中国）有限公司。由于该复审目前仍在USPTO审查中，当前阶段该复审对本集团无潜在影响。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01477":"欧康维视生物-B","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","BK1191":"制药","BK1161":"生物科技","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","BK1515":"抗疫概念","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK1574":"生物医药B类股","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1521":"挪威政府全球养老基金持仓","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","01093":"石药集团","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","01672":"歌礼制药-B","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H"},"translate_title":"Ascletis Pharmaceuticals: CSPC subsidiary challenges an authorized patent due to the consistent molecular structure of the compound","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"01672":1,"01093":1},"content_text":"近日，歌礼制药发布自愿性公告。披露公司近日获悉由石药集团有限公司附属公司康久普乐生物医疗有限公司向美国专利商标局（“USPTO”）提交的一项复审。该复审质疑本公司附属公司歌礼制药（中国）有限公司一项已获授权的美国专利的有效性。截至本公告日期，该复审仍在USPTO审查中。石药尚在专利申请中的化合物10（Compound 10，申请号：PCT/CN2024/140920；申请人：石药集团百克（山东）生物制药股份有限公司（CSPC Baike (Shandong)Biopharmaceutical Co., Ltd.））与歌礼已获USPTO授权的该专利所涵盖的化合物1(Compound 1)分子结构完全一致。但歌礼向USPTO提交专利申请的日期领先石药申请的日期长达三个多月之久，截至本公告日期，石药的专利申请仍在审查中。尽管本公司尚无法推测石药提交该复审的动机，但值得注意的是，在2025年3月下旬，本公司的管理层曾收到由石药主动提出的、关于该专利涵盖的GLP-1R激动剂化合物1的全球授权许可请求，本公司婉拒。该专利系利用歌礼专有技术开发而成，目前正应用于本公司候选药物ASC30的研发。本公司包括化合物1和ASC30在内的化合物受多项专利保护，包括前述该专利。基于其与现有技术相比具有新颖性和非显而易见性，USPTO已于2025年2月25日将该专利权授予本公司附属公司歌礼制药（中国）有限公司。本公司对于该专利的有效性充满信心，如该复审继续推进，本公司将采取一切必要的法律手段捍卫本公司的知识产权。由于该复审目前仍在USPTO审查中，当前阶段该复审对本集团无潜在影响。本公司将密切关注该复审的进展并评估其影响，与此同时，当前本公司的业务及运营未受影响。（企业公告）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2548026544","isCrawlerRequest":true}